Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397254 · ClinicalTrials.gov registry record · Phase 4
Two Rizatriptan Prescribing Portions for Treatment of Migraine
A Phase 4 study of Migraine, sponsored by Clinvest.
- Completed
- Registry status
- Phase 4
- Development phase
- 197
- Enrollment target
- 10
- Study locations
NCT00397254: Completed Phase 4 study of Migraine, sponsored by Clinvest.
NCT00397254 is a Phase 4 study of Migraine that has completed, run by Clinvest. The registered enrollment target is 197 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (45% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397254, a Phase 4 study of Migraine, has completed, sponsored by Clinvest.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 197 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
Conditions Studied
Interventions
- DRUG rizatriptan
Study Locations (10)
California
- Brian Koffman, MD - Diamond Bar
- San Francisco Clinical Research Center - San Francisco
Missouri
- Clinvest - Springfield
- Mercy Health Research / Ryan Headache Center - St Louis
Florida
- Physician Associates - Oviedo
Georgia
- Dr. B. Abraham, PC - Snellville
Maryland
- Dhiren Shah, MD - Prince Frederick
Michigan
- Westside Family Medical Center - Kalamazoo
North Carolina
- PharmQuest - Greensboro
Pennsylvania
- Thomas Jefferson University Hospital Jefferson Headache Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
What the finished NCT00397254 record still lists
NCT00397254 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which rizatriptan is the first listed.
NCT00397254 lists 10 locations in 8 states (California, Missouri, Florida).
Frequently Asked Questions
What is clinical trial NCT00397254 about?
NCT00397254 is a clinical study titled "Two Rizatriptan Prescribing Portions for Treatment of Migraine". The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
What is the current status of trial NCT00397254?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 197 participants. The study started on 2006-12. Estimated completion is 2008-01.
What conditions does trial NCT00397254 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00397254?
The interventions under investigation include: rizatriptan (DRUG).
Who is sponsoring clinical trial NCT00397254?
This trial is sponsored by Clinvest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397254 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00397254's enrollment target sits among peer trials
197 42nd of 102 higher than 61 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia